Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

23.75 -0.13 (-0.54%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market. 
Via The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Unveiling 4 Analyst Insights On AnaptysBio
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseeing stock surge amid clinical milestones. Analysis compares PD-1 agonist... 
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
From AnaptysBio, Inc.
Via GlobeNewswire
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
From AnaptysBio, Inc.
Via GlobeNewswire
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
AnaptysBio Announces Participation in Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.